A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
Clinical trial NCT04291248 · UNKNOWN
Trial details
- NCT number
- NCT04291248
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-01
- Primary completion
- 2022-12-01
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.